

BBC

Virtus Biotech Clinical Trials ETF

Analyst Report

BBC tracks an equally weighted index of US-listed biotech companies with lead drugs in various phases of clinical trials.

ESG Themes and Scores

3.45/10

ESG Rate

1.05%

Global Percentile

2.09%

Peer Percentile

Performance Data

	BBC	ETF Database Category Average	Factset Segment Average
1 Month	-1.96%	3.82%	-1.96%
3 Month	4.17%	2.50%	4.17%
YTD Return	11.41%	2.65%	11.41%
1 Year Return	123.07%	28.42%	123.07%
3 Year Return	21.00%	7.32%	21.00%
5 Year Return	-1.47%	1.13%	-1.47%

Top 5 Holdings

Symbol	Holding	% Assets
ERAS	Erasca, Inc.	2.83%
RZLT	Rezolute, Inc.	1.92%
TNGX	Tango Therapeutics, Inc.	1.82%
SYRE	Spyre Therapeutics, Inc.	1.79%
ELVN	Enliven Therapeutics, Inc.	1.62%

Vitals

Issuer	Virtus Investment Partners
Brand	Virtus
Structure	ETF
Expense Ratio	0.65%
Inception	Dec 16, 2014
Index Tracked	LifeSci Biotechnology Clinical Trials Index

ETF Database Themes

Category	Health & Biotech Equities
Asset Class	Equity
Asset Class Size	Multi-Cap
Asset Class Style	Blend
Region (General)	North America
Region (Specific)	U.S.

FactSet Classifications

Segment	Equity: U.S. Life Sciences Tools & Services
Category	Sector
Focus	Health Care
Niche	Life Sciences Tools & Services
Strategy	Equal
Weighting	Equal